Runben Biotechnology (SH:603193) Xin Lang Cai Jing·2025-09-12 00:26Core Viewpoint - The company reported a revenue of 895 million yuan for the first half of 2025, reflecting a year-on-year growth of 20.3%, while the net profit attributable to shareholders was 188 million yuan, up 4.2% year-on-year [1] Revenue and Profit Analysis - In Q2 2025, the company achieved a revenue of 655 million yuan, representing a year-on-year increase of 13.5%, but the net profit attributable to shareholders decreased by 0.8% to 143 million yuan [1] - The company's net profit margin declined by 3.2 percentage points in H1 2025, primarily due to a 0.6 percentage point drop in gross margin and a 1.5 percentage point increase in sales expense ratio [3] Product Category Performance - In H1 2025, sales for mosquito repellent, baby care, and essential oils were 375 million, 405 million, and 92 million yuan respectively, with year-on-year changes of +13%, +39%, and -15% [2] - In Q2, mosquito repellent and baby care products grew by 14% and 23% respectively, while essential oils saw a decline of 16% [2] Channel Expansion - The company has strengthened its online channel presence while expanding offline channels, maintaining a high market share on platforms like Tmall, JD, and Douyin, and has initiated cooperation with Sam's Club [2] - The company has developed non-platform distribution channels, including partnerships with major retailers such as Yonghui and Walmart, which is expected to further solidify brand sales [2] Investment Outlook - The company continues to innovate its product offerings and faces temporary profit pressure due to increased promotional expenses [3] - The expected EPS for 2025-2027 is projected to be 0.82, 1.04, and 1.30 yuan per share, maintaining a "buy" rating [3]